Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI311 in Steroid-resistant Thyroid Associated Ophthalmopathy
NCT06269393Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sycume in thyroid associated ophthalmopathy (TAO), sponsored by Peking University People's Hospital. Started Jan 2024; status: completed.
02
Drugs
sycume
03
Conditions
thyroid associated ophthalmopathy (TAO)
Beyond the preview
Go deeper on NCT06269393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06269393.